New stock news | Before the formal announcement, the Hong Kong Stock Exchange receives the disclosure.

According to the disclosure by the Hong Kong Stock Exchange on January 9th, Xiansheng Pharmaceutical Limited (Xiansheng Pharma) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Morgan Stanley and CICC acting as its joint sponsors. The prospectus shows that Xiansheng Pharma was originally engaged in oncology business by SIMCERE PHARMA in 2006, and was established in 2020, focusing on the research, development, and commercialization of innovative oncology drugs. It currently has five commercially available innovative drugs, over 15 high-potential candidate drugs in clinical and IND declaration preparation stages, as well as multiple discovery projects. According to the ZUDE Financial Advisory report, by 2025, the company completed three external licensing transactions, ranking first and fourth in terms of the number and total value of oncology asset transactions in SINO BIOPHARM company.